The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Naftidrofuryl for intermittent claudication
|
|---|---|
| Published in |
Cochrane database of systematic reviews, December 2012
|
| DOI | 10.1002/14651858.cd001368.pub4 |
| Pubmed ID | |
| Authors |
Tine LM de Backer, Robert Vander Stichele, Philippe Lehert, Luc Van Bortel |
| Abstract |
Lifestyle changes and cardiovascular prevention measures are a primary treatment for intermittent claudication (IC). Symptomatic treatment with vasoactive agents (Anatomic Therapeutic Chemical Classification (ATC) for medicines from the World Health Organisation class CO4A) is controversial. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Egypt | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 228 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Unknown | 227 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 35 | 15% |
| Student > Bachelor | 25 | 11% |
| Researcher | 22 | 10% |
| Student > Ph. D. Student | 21 | 9% |
| Other | 12 | 5% |
| Other | 32 | 14% |
| Unknown | 81 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 71 | 31% |
| Nursing and Health Professions | 19 | 8% |
| Psychology | 10 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
| Sports and Recreations | 7 | 3% |
| Other | 26 | 11% |
| Unknown | 85 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2020.
All research outputs
#7,281,781
of 26,393,590 outputs
Outputs from Cochrane database of systematic reviews
#8,609
of 13,215 outputs
Outputs of similar age
#68,917
of 291,941 outputs
Outputs of similar age from Cochrane database of systematic reviews
#107
of 195 outputs
Altmetric has tracked 26,393,590 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 13,215 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.7. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,941 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 195 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.